MultiCell Technologies Inc (MCET)

[woodstock135]

MultiCell Technologies receives European patent for cancer therapies

Apr 26, 2011 (Datamonitor via COMTEX News Network) --
MultiCell Technologies, Inc., a clinical-stage bio-pharmaceutical company, has received a European patent covering certain of its therapeutic agents for the treatment of cancer.

MultiCell has created a new class of recombinant antibody therapeutics which redirect the immune response to specific cancer targets corresponding to the peptides engrafted onto the recombinant antibody. Such compositions are able to transform seemingly ineffective peptides into potent antibody therapeutics with a different mechanism of action compared to that of conventional antibody therapeutics currently in clinical use.

These recombinant antibody therapeutics not only produce a potent immune response, but also stimulate the generation of cytolytic cells, and Interferon-gamma and Interleukin-2 producing T-cells. When coupled with MultiCell's dsRNA therapeutics, this new class of recombinant antibody therapeutics has been shown in animal models to eradicate cancer and generate immune protection against the reoccurrence of malignant tumors.

"We are very pleased that the European Patent Office has decided to grant us a patent covering our novel compositions and method for the treatment of cancer as well as for the treatment of infectious disease," stated Jerry Newmin, Chairman and CEO of MultiCell Technologies. "Our technology uses the antibody molecule as a platform to better present a peptide to immune cells thereby increasing the overall immune response to the peptide," Mr Newmin added.


http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

Copyright (C) 2011 Datamonitor. All rights reserved